ClinicalTrialsFinder

Phase 1 Amyotrophic Lateral Sclerosis Clinical Trials

14 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–14 of 14 trials

Recruiting
Phase 1

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis
Insmed Gene Therapy LLC23 enrolled5 locationsNCT07290062
Recruiting
Phase 1Phase 2

Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

Amyotrophic Lateral Sclerosis
Vector Y Therapeutics12 enrolled11 locationsNCT07287397
Recruiting
Phase 1

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

ALS (Amyotrophic Lateral Sclerosis)
Eli Lilly and Company32 enrolled12 locationsNCT07100119
Recruiting
Phase 1

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Amisodin in Healthy Adult Subjects With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis
PRG Science & Technology Co., Ltd.48 enrolled1 locationNCT07221240
Recruiting
Phase 1Phase 2

Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis
Biogipuzkoa Health Research Institute90 enrolled1 locationNCT07414212
Recruiting
Phase 1

Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis

ALS (Amyotrophic Lateral Sclerosis)
Celosia Therapeutics Pty Ltd15 enrolled1 locationNCT07401121
Not Yet Recruiting
Phase 1

A study to assess safety, tolerability, and pharmacokinetics of RTX-001/101 in healthy adults. Part 1A and Part B healthy participants only

Amyotrophic Lateral Sclerosis
Repeat Therapeutics Pty Ltd104 enrolled1 locationACTRN12625001215415
Recruiting
Phase 1

Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral SclerosisALS
Sunnybrook Health Sciences Centre6 enrolled1 locationNCT07193953
Recruiting
Phase 1

A Study to Evaluate the Safety and Pharmacokinetics of Single and Multiple Doses of Prosetin in Healthy Volunteers and Participants With ALS

Amyotrophic Lateral Sclerosis
ProJenX72 enrolled4 locationsNCT05279755
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation

Amyotrophic Lateral Sclerosis
Ractigen Therapeutics.32 enrolled3 locationsNCT06556394
Recruiting
Phase 1Phase 2

TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis
Talengen Institute of Life Sciences, Shenzhen, P.R. China.60 enrolled1 locationNCT06726577
Recruiting
Phase 1Phase 2

Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS

Amyotrophic Lateral Sclerosis
Xuanwu Hospital, Beijing38 enrolled1 locationNCT06598202
Completed
Phase 1

An open-label, phase 1b study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of PMX205 in patients with amyotrophic lateral sclerosis

Amyotrophic Lateral SclerosisMotor Neuron DiseaseParkinson's Disease
Alsonex Pty Ltd8 enrolled1 locationACTRN12622000927729
Completed
Phase 1

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of mEphA4-Fc

Amyotrophic Lateral Sclerosis
NuNerve Pty. Ltd.28 enrolled1 locationACTRN12621000514808